Novavax(NASDAQ) NVAX

Novavax, Inc. makes vaccines that protect people from getting sick from viruses. Its products help doctors and health agencies stop the spread of infectious diseases. The company uses a special technology to boost the strength of the body's immune system.

Core Vaccine Products

• COVID-19 Vaccines: Protein-based immunization products for adults and high-risk groups; includes the JN.1 variant version.
• Matrix-M Adjuvant: Proprietary immune booster that helps vaccines induce stronger and longer-lasting protection.
• Malaria Vaccine: Partner-led shot for children in endemic regions; distributed in 25 countries as of May 2026.
• Early-Stage Pipeline: Development programs for shingles and C. difficile vaccines; aimed at areas with unmet medical needs.

Strategic Growth and Expansion

• Partnered with Sanofi in May 2024 to lead global sales of COVID-19 vaccines and develop new combination shots.
• Amended the Sanofi agreement in Sept. 2025 to include the company's proprietary adjuvant in a pandemic influenza program.
• Granted Pfizer a license in Jan. 2026 to use its immune-boosting technology in two infectious disease areas.
• Expanded the use of its technology into over 30 unique fields, including cancer research, by April 2026.

Technical and Operational Strengths

Novavax uses recombinant nanoparticle technology to produce antigens that trigger an immune response without using live viruses. The company relies on a network of global pharmaceutical partners to manufacture and sell its products in major international markets.

The Financial Scorecard

• Market cap reached $1.3 billion in Q1 2026, up 28.7% year over year.
• Total revenue was $196.2 million for the six-month period ended June 30, 2026.
• Selling, general, and administrative expenses fell to $55.4 million for the six months ended June 30, 2026.
• Cash, cash equivalents, and marketable securities totaled $723.9 million as of June 30, 2026.
• Net loss for the three months ended June 30, 2026 was $0.32 per share.

Bottom Line

Novavax has transitioned from a standalone vaccine manufacturer into a technology partner for the world's largest pharmaceutical companies. Its focus on licensing its proprietary adjuvant technology supports a less capital-intensive business model.